-
1
Efficacy and Safety of Low-Dose Lenvatinib and Toripalimab in Patients With Recurrent Platinum-Resistant Ovarian Cancer: Study Protocol of a Multicenter, Open-Label, Single-Arm, Ph...
Published 2025-02-01“…Exploratory objectives aim to identify biomarkers and molecular signatures for predicting response or prognosis.Keywords: ovarian cancer, platinum-resistant, immune checkpoint inhibitor, lenvatinib, dose adjustment…”
Get full text
Article -
2
Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumab
Published 2025-02-01Get full text
Article -
3
GNA15 predicts poor outcomes as a novel biomarker related to M2 macrophage infiltration in ovarian cancer
Published 2025-02-01Get full text
Article -
4